Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17676166 | 0.76 | ALDH1A1 (0.35) | PDE10AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL12146965 | 0.75 | POLB (0.53) | PDE10AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL1093205 | 0.68 | EGFR (0.34) | MAPTALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL7738685 | 0.67 | NUDT1 (0.31) | — | |
| SCHEMBL10195823 | 0.67 | MEN1 (0.34) | PDE10AMEN1KMT2APDE4D | |
| SCHEMBL5260391 | 0.63 | PDE10A (0.62) | PDE10AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL29684098 | 0.61 | TDP1 (0.48) | PDE10AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL7478482 | 0.60 | ALDH1A1 (0.64) | PDE10AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL544726 | 0.59 | MAPK1 (0.47) | PDE10AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL949962 | 0.59 | PDE10A (1.00) | PDE10AMAPTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| WO-2009152083-A1 | 5H-PYRR0L0 [2,3-B] PYRAZINE DERIVATIVES FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152087-A1 | BICYCLIC HETEROARYL COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, PRKACA, RAF1 | PDE10A 831/4885MAPT 3110/4885ALDH1A1 1732/4885 |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKACA, KIT, FLT3 | PDE10A 833/4885MAPT 4189/4885ALDH1A1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.